Goldman still sees Alkermes ALKS 3831 ‘unlikely to be practice changing’

After Alkermes presented additional details on efficacy and safety, as well as the first look at the metabolic data from the Enlighten-2 trial and interim data from the ongoing extension study, Goldman Sachs analyst Terence Flynn continues to believe the company’s schizophrenia drug ALKS 3831 is “unlikely to be practice changing.” The analyst reiterates a Sell rating on the shares with a $27 price target. ALKS 3831 demonstrated a comparable metabolic profile relative to Zyprexa over the 24-week portion of the trial, Flynn tells investors in a research note. The analyst believes an outstanding question remains with respect to potential long term type 2 diabetes risk. It is unclear if the existing ALKS 3831 data will be enough to drive a differentiated label for the drug versus Zyprexa in this regard, which could have commercial implications, says the analyst.

https://thefly.com/landingPageNews.php?id=2892073